newwin
Luciann Nguyen
Settings
← Trials
NCT06162221phase 1 2recruiting

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Revolution Medicines, Inc.

ClinicalTrials.gov
616
Enrollment · estimated
13
Countries · 93 sites
2027-06
Primary completion
2 mo ago
Record updated
Commercial relevance

Trial record references molecular eligibility required.

Molecular eligibility required
Biomarker requirement language
  • Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)
  • Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B)
  • Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D)
Change timeline

No changes detected yet. The first refresh records a baseline snapshot; subsequent refreshes generate field-level changes.

Signals from this trial
  • New trial
    55/100
    Opportunity

    New phase 1_2 trial NCT06162221 posted by Revolution Medicines, Inc.: "Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC".

    ClinicalTrials.gov record updated 70 days ago.

Eligibility — raw, for validation
Inclusion criteria:

All Patients (unless otherwise noted):

* ≥ 18 years of age
* ECOG PS is 0 to 1
* Adequate organ function as outlined by the study
* Received prior standard therapy appropriate for tumor type and stage
* Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)
* Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B)
* Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D)

Exclusion criteria:

All Patients:

* Primary central nervous system (CNS) tumors
* Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs
* Major surgery \< 28 days of first dose
* Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids

Other inclusion/exclusion criteria may apply.